238 related articles for article (PubMed ID: 33145772)
1. Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodeling.
Gonzalez EA; Tobar Leitão SA; Soares DDS; Tavares AMV; Giugliani R; Baldo G; Matte U
J Inherit Metab Dis; 2021 May; 44(3):740-750. PubMed ID: 33145772
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.
Osborn MJ; Webber BR; McElmurry RT; Rudser KD; DeFeo AP; Muradian M; Petryk A; Hallgrimsson B; Blazar BR; Tolar J; Braunlin EA
J Inherit Metab Dis; 2017 Mar; 40(2):281-289. PubMed ID: 27743312
[TBL] [Abstract][Full Text] [Related]
3. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
[TBL] [Abstract][Full Text] [Related]
4. Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.
Baldo G; Tavares AM; Gonzalez E; Poletto E; Mayer FQ; Matte UD; Giugliani R
Cardiovasc Pathol; 2017; 27():45-50. PubMed ID: 28104572
[TBL] [Abstract][Full Text] [Related]
5. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
[TBL] [Abstract][Full Text] [Related]
6. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
7. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
[TBL] [Abstract][Full Text] [Related]
8. Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).
Barbosa Mendes A; do Nascimento CC; D'Almeida V
PLoS One; 2019; 14(12):e0220429. PubMed ID: 31834922
[TBL] [Abstract][Full Text] [Related]
9. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I.
Kuehn SC; Koehne T; Cornils K; Markmann S; Riedel C; Pestka JM; Schweizer M; Baldauf C; Yorgan TA; Krause M; Keller J; Neven M; Breyer S; Stuecker R; Muschol N; Busse B; Braulke T; Fehse B; Amling M; Schinke T
Hum Mol Genet; 2015 Dec; 24(24):7075-86. PubMed ID: 26427607
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I mice.
Gonzalez EA; Martins GR; Tavares AMV; Viegas M; Poletto E; Giugliani R; Matte U; Baldo G
Life Sci; 2018 Mar; 196():102-109. PubMed ID: 29366749
[TBL] [Abstract][Full Text] [Related]
11. Mucopolysaccharidosis type I.
Wraith JE; Jones S
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
[TBL] [Abstract][Full Text] [Related]
12. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.
Liu Y; Xu L; Hennig AK; Kovacs A; Fu A; Chung S; Lee D; Wang B; Herati RS; Mosinger Ogilvie J; Cai SR; Parker Ponder K
Mol Ther; 2005 Jan; 11(1):35-47. PubMed ID: 15585404
[TBL] [Abstract][Full Text] [Related]
13. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.
Schuh RS; Gonzalez EA; Tavares AMV; Seolin BG; Elias LS; Vera LNP; Kubaski F; Poletto E; Giugliani R; Teixeira HF; Matte U; Baldo G
Gene Ther; 2020 Feb; 27(1-2):74-84. PubMed ID: 31827259
[TBL] [Abstract][Full Text] [Related]
14. Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.
do Nascimento CC; Aguiar O; Viana GM; D Almeida V
Reprod Fertil Dev; 2020 Feb; 32(3):304-312. PubMed ID: 31679559
[TBL] [Abstract][Full Text] [Related]
15. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome.
Braunlin E; Mackey-Bojack S; Panoskaltsis-Mortari A; Berry JM; McElmurry RT; Riddle M; Sun LY; Clarke LA; Tolar J; Blazar BR
Pediatr Res; 2006 Jan; 59(1):27-32. PubMed ID: 16326988
[TBL] [Abstract][Full Text] [Related]
16. Optimization of alginate microcapsules containing cells overexpressing α-l-iduronidase using Box-Behnken design.
Diel D; Lagranha VL; Schuh RS; Bruxel F; Matte U; Teixeira HF
Eur J Pharm Sci; 2018 Jan; 111():29-37. PubMed ID: 28882767
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
18. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.
Clarke LA; Russell CS; Pownall S; Warrington CL; Borowski A; Dimmick JE; Toone J; Jirik FR
Hum Mol Genet; 1997 Apr; 6(4):503-11. PubMed ID: 9097952
[TBL] [Abstract][Full Text] [Related]
19. Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.
Baldo G; Mayer FQ; Martinelli B; Dilda A; Meyer F; Ponder KP; Giugliani R; Matte U
Behav Brain Res; 2012 Jul; 233(1):169-75. PubMed ID: 22580166
[TBL] [Abstract][Full Text] [Related]
20. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
